Citations

Clear

2303 citation(s) found for "Yu, Edward".

Gender Differences in Time Spent on Documentation and the Electronic Health Record in a Large Ambulatory Network
Fong, Allan S., Jeffery, Molly M. , Sinsky, Christine A. , Goldstein, Richard , Williams, Brian , Melnick, Edward R. , Jeffery, Molly Moore , Melnick, Edward R , Rotenstein, Lisa S.

Mayo Clinic

JAMA Network Open | March 24, 2022 | Volume: 5 | Issue: 3 | Pages: e223935

10.1001/jamanetworkopen.2022.3935 | PMID 35323954 Get It

Product characteristics should be reported in all biological therapy publications
Buchheit, Thomas Edward , Hunt, Christine , Eldrige, Jason S. , Eshraghi, Yashar , Souza, Dmitri , Buchheit, Thomas , Eldrige, Jason, Hunt, Christine

Mayo Clinic

Regional Anesthesia & Pain Medicine | March 22, 2022 | Volume: 47 | Issue: 7 | Pages: 449.1-449

10.1136/rapm-2022-103557 | PMID 35318261 Get It

Clinical, Endoscopic, and Histopathology Features of Esophageal Graft-vs-Host Disease
Kamboj, Amrit K. , Yarlagadda, Manoj, Ricaurte, Luisa , Hagen, Catherine E. , Katzka, David A. , Agarwal, Siddharth , Yarlagadda, Manoj K., Archila, Luisa Ricaurte, Agarwal, Siddharth , Hagen, Catherine E , Agarwal, Siddharth

Mayo Clinic

American Journal of Gastroenterology | March 21, 2022 | Volume: 117 | Issue: 7 | Pages: 1154-1157

10.14309/ajg.0000000000001738 | PMID 35311761 Get It

INTRODUCTION: To describe the clinical, endoscopic, and histopathology features of esophageal graft-vs-host disease (GVHD). Methods: Patients with biopsy-proven esophageal GVHD diagnosed at Mayo Clinic between 2000 and 2021 were included. Results: In 43 esophageal patients, other organ GVHD was present in 58% before and 86% at esophageal GVHD diagnosis. Esophageal specific symptoms were uncommon (dysphagia 26% and odynophagia/heartburn 5%). Esophagogastroduodenoscopy was abnormal in 72% patients demonstrating erosive esophagitis, ulceration, desquamation, or rings/furrows in a diffuse or focal pattern. DISCUSSION: There should be a low threshold for esophageal biopsies for GVHD because esophageal symptoms and endoscopic findings may be nonspecific or absent.
Abstract 156: SAMMPRIS Angiography Discloses Hemodynamic Effects of Intracranial Stenosis: Computational Fluid Dynamics of Fractional Flow
Fong, Albert K, Scalzo, Fabien , Cloft, Harry J. , Chimowitz, Marc I. , Feldmann, Edward, Investigators, for the SAMMPRIS, Liebeskind, David S. , Lynn, Michael , Derdeyn, Colin P. , Fiorella, David , Investigators, for the SAMMPRIS

Mayo Clinic

Stroke | March 20, 2022 | Volume: 44 | Issue: suppl_1 | Pages: No page available

10.1161/str.44.suppl_1.a156 Get It

Background: Pressure gradients across an intracranial stenosis, or fractional flow (FF), may identify the hemodynamic significance of symptomatic lesions. Computational fluid dynamic (CFD) simulations on 3D morphology of such lesions can calculate these pressure gradients and model effects of systemic physiology interacting with these lesions, such as hypotension and induced hypertension. We studied SAMMPRIS angiography to calculate FF across symptomatic intracranial stenoses and modeled the downstream effect of systemic blood pressure (BP) fluctuations. Methods: Conventional angiography of symptomatic intracranial stenoses in the SAMMPRIS trial was converted from biplanar images to a 3D geometric mesh. CFD simulations were conducted with Ansys CFX on a Cray supercomputer to calculate FF derived from distal/proximal pressure gradients for each of 3 inflow conditions: normal BP (120/80 mm Hg), hypotension (90/60 mm Hg) and hypertension (180/120 mm Hg). Abnormal FF was defined as ≤ 0.8 during diastole to define hemodynamic significance of a stenosis. Results: 407 patients with 70-99% symptomatic stenosis had conventional angiography with biplanar views available for 3D reconstruction in 249, and CFD simulations in 188 (25 VA, 45 BA, 32 ICA, 86 MCA). Under simulated normal inflow conditions (120/80 mm Hg), only 76/188 (40%) cases had low FF. During simulated hypertension, FF improved to normal in 10/188 (5%) cases. Simulated hypotension caused FF to worsen from normal in 12/188 (6%) cases. Other hemodynamic parameters including shear stress could also be calculated and visually depicted in all cases. Conclusions: CFD and hemodynamic modeling of FF can be retrospectively performed after 3D conversion of biplanar angiogram views. FF estimates predict that only 40% of severe (70-99%) symptomatic intracranial stenoses are hemodynamically significant. Systemic BP fluctuations can be modeled during phases of the cardiac cycle to show downstream flow changes.
Abstract 233: Patient Factors Minimally Impact Experience with Informed Consent Documents for Percutaneous Coronary Intervention
Coylewright, Megan , Gosch, Kensey , McNulty, Edward, Ting, Henry H. , Spertus, John A.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | March 20, 2022 | Volume: 5 | Issue: suppl_1 | Pages: No page available

10.1161/circoutcomes.5.suppl_1.a233 Get It

Background: In light of well-known deficiencies in the process of informed consent for percutaneous coronary intervention (PCI), we developed and tested a personalized consent form, PRISM; this was shown to improve patients' participation in the consent process, understanding of procedural risks, and engagement in shared decision-making when compared to original PCI consent forms. It is unknown whether patient factors traditionally known to impair the consent process, including socioeconomic status, literacy and numeracy, were associated with greater benefit from the PRISM consents. Methods: We interviewed 590 patients receiving original consent documents and 527 receiving PRISM consents and compared the rates of reviewing the consent form, recalling a risk of bleeding and engaging in discussions about stent type using hierarchical modified Poisson regression analysis. The interaction of patient factors (age, gender, education level, insurance status, literacy and numeracy) with PRISM on outcomes was assessed. Results: Overall, few patient characteristics were associated with outcomes, including review of consent forms, knowledge transfer, or engagement in shared decision-making (see Table), although older patients were less likely to discuss stent types with their doctors (RR=0.84/decade for original and 0.93/decade for PRISM). Those with more than a high school education were less likely to review original consents (RR=0.77; 95% CI=0.66, 0.89) compared to those with less education; this difference was eliminated with the PRISM consents (RR=1.0; 95%CI=0.82, 1.23; p-value for interaction = 0.01). Conclusions: PRISM consent forms led to improved participation in the consent process and knowledge transfer in a 9-center study; there was little variance by sociodemographic, economic, literacy or numeracy factors, both with original consents and with PRISM.
Abstract 157: The Relationship between Readmission Cost and Total Cost Over Time for Heart Failure
Burke, Joseph , Westrich, James L., Savitz, Lucy A., Wennberg, David E., Havranek, Edward P. , Burke, Joseph M, Weeks, William Brinson , Dunlay, Shannon M.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | March 20, 2022 | Volume: 6 | Issue: suppl_1 | Pages: No page available

10.1161/circoutcomes.6.suppl_1.a157 Get It

Background: The dominant healthcare payment model in the US, fee-for-service, provides incentives to deliver costlier care for heart failure and disincentives to deliver higher quality care. One proposed method to align cost and quality incentives is to impose financial penalties on providers when patients are readmitted within 30 days after a heart failure hospitalization. We hypothesized that this strategy might not lower overall costs, because lower readmission costs might be offset by higher non-readmission post-acute care costs. Methods: We studied cost to Medicare from 2008-09 for all heart failure hospitalizations (MS-DRG 291, 292, or 293) in the 15 healthcare delivery systems participating in the High Value Health Collaborative. We categorized costs for the 30, 90, and 180 days after the day of admission for first heart failure hospitalization in the study period into acute care costs (inpatient care, outpatient facility costs with 3 day look back window, part B professional fees), inpatient readmission cost, and non-readmission post-acute care costs (outpatient facility fee, sub-acute rehab, inpatient rehab, long term care, home health care, part B professional fees). Results: Using the most common MS DRG (DRG 292) as an example, across the 15 healthcare systems, we found wide variation in median total costs for the 30- ($6487-$11565), 90- ($8049-$18918), and 180- ($9844-$24752) day time frames. For the 30-day time frame, readmission costs ($700 - $2684) and non-readmission post-acute care costs ($477 - $6398) also showed wide variation. The Figure is a plot of these two costs, with bubbles sized to reflect the number of cases for the hospital system (30-day time frame); results were comparable for 90 and 180 days. Contrary to our hypothesis, we found no inverse relationship between readmission costs and non-readmission post-acute care costs. These data do not account for possible differences in case mix and in geographic differences in labor and facility costs. Conclusions: Non-readmission post-acute costs for heart failure are unrelated to readmission costs but were greater than readmission costs in a number of healthcare deliver systems, raising questions about the overall value to the healthcare systems of an exclusive focus on readmission as a strategy for reducing the costs of heart failure.
Clinical Course and Impact of Immune Checkpoint Inhibitor Colitis Resembling Microscopic Colitis
Fredrick, Thomas , Ramos, Guilherme Piovezani , Neto, Manuel B. Braga , Kane, Sunanda V. , Faubion, William A. , Loftus, Edward V. , Pardi, Darrell S. , Pasha, Shabana F., Farraye, Francis A. , Zhang, Lizhi , Raffals, Laura E. , Fredrick, Thomas W , Ramos, Guilherme P , Braga Neto, Manuel B , Kane, S , Loftus, Edward V , Farraye, Francis A

Mayo Clinic

Crohn's & Colitis 360 | March 14, 2022 | Volume: 4 | Issue: 2 | Pages: No page available

10.1093/crocol/otac008 | PMID 36777041 Get It

Abstract Background Microscopic colitis (MC) is suspected to result from increased immune activity in gut mucosa. Immune checkpoint inhibitors (ICIs) treat cancer by activating the immune system, and further investigation is needed regarding their role in the development of MC. Methods A retrospective case series investigated cases of endoscopically and histologically confirmed MC developing after administration of ICIs. Clinical notes and medication administration records were reviewed for demographics, symptom duration, and treatment response. Results Nineteen cases of de novo MC were identified, with 95% of cases requiring steroid treatment, 53% presenting with hospitalization, and colitis-related mortality in 1 individual. Symptom onset occurred a median of 160 days after initiation of ICI therapy and 53 days after their most recent dose of therapy. Patients had a median of 125 days of symptoms, and ICI therapy was held in 70% of individuals due for treatment. Conclusions MC can develop after ICI administration, and presents with severe symptoms, often requiring hospitalization and steroid treatment. In certain individuals this can require a prolonged treatment course of steroid therapy or immunomodulators. Individuals developing diarrhea after ICI therapy warrant thorough workup including endoscopy and rapid treatment initiation given the disease severity observed in this series.
A United States expert consensus to standardise definitions, follow‐up, and treatment targets for extra‐intestinal manifestations in inflammatory bowel disease
Falloon, Katherine , Cohen, Benjamin L., Ananthakrishnan, Ashwin N. , Barnes, Edward L. , Bhattacharya, Abhik , Colombel, Jean‐Frédéric , Driscoll, Marcia S., Ha, Christina , Horst, Sara , Hou, Jason K. , Husni, M. Elaine , Lowder, Careen Y. , Martin, George M. , Sayed, Christopher J. , Schocket, Lisa S. , Siaton, Bernadette C. , Vedak, Priyanka , Rieder, Florian , Colombel, J F. , Horst, Sara , Rieder, Florian , Ananthakrishnan, A N , Sayed, Christopher , Barnes, Edward L , Cross, Raymond K. , Fernandez, Anthony P , Herfarth, Hans , Kroshinsky, Daniela , Kuhn, Kristine A. , Parikh, Deep , Weisman, Michael H.

Mayo Clinic

Alimentary Pharmacology & Therapeutics | March 12, 2022 | Volume: 55 | Issue: 9 | Pages: 1179-1191

10.1111/apt.16853 | PMID 35277863 Get It

SummaryBackground and aimsExtra‐intestinal manifestations (EIMs) are a common complication of inflammatory bowel diseases (IBD), affecting up to half of the patients. Despite their high prevalence, information on standardised definitions, diagnostic strategies, and treatment targets is limited.MethodsAs a starting point for a national EIM study network, an interdisciplinary expert panel of 12 gastroenterologists, 4 rheumatologists, 3 ophthalmologists, 6 dermatologists, and 4 patient representatives was assembled. Modified Delphi consensus methodology was used. Fifty‐four candidate items were derived from the literature review and expert opinion focusing on five major EIMs (erythema nodosum, pyoderma gangrenosum, uveitis, peripheral arthritis, and axial arthritis) were rated in three voting rounds.ResultsFor use in a clinical practice setting and as part of the creation of a prospective registry of patients with EIMs, the panel developed definitions for erythema nodosum, pyoderma gangrenosum, uveitis, peripheral arthritis, and axial arthritis; identified the appropriate and optimal subspecialists to diagnose and manage each; provided methods to monitor disease course; offered guidance regarding monitoring intervals; and defined resolution and recurrence.ConclusionsConsensus criteria for appropriate and optimal means of diagnosing and monitoring five EIMs have been developed as a starting point to inform clinical practice and future trial design. Key findings include straightforward diagnostic criteria, guidance regarding who can appropriately and optimally diagnose each, and monitoring options that include patient and physician‐reported outcomes. These findings will be used in a national multicenter study network to optimise the management of EIMs.
Abstract P4-12-01: Adherence with adjuvant endocrine therapy with or without Palbociclib in the PALLAS trial
Zahrieh, David M. , Zdenkowski, Nick, Bjelic‐Radisic, Vesna , Naughton, Michelle J. , Pfeiler, Georg , Gelmon, Karen, Jiménez, M. Martín, Haddad, Tufia C. , Ring, Alistair Edward, Lorenzo, Jose JuanPonce, Sabanathan, Dhanusha , Burstein, H.J., Nowecki, Zbigniew , Pristauz-Telsnigg, Gunda, Bellet-Ezquerra, M., Muehlbacher, Karoline, Partridge, Ann, Zoroufy, Alex, Fesl, Christian , Shinn, Eileen H. , DeMichele, Angela , Lemieux, Julie , Mao, Jun J. , Mayer, Ingrid A. , Egle, Daniel , Zoppoli, Gabriele M. , Traina, Tiffany A , Antolín, Silvia , Chan, Arlene , Wolff, Antonio C. , Lorenzo, Jose Juan Ponce, Brufsky, Adam , Ezquerra, Meritxell Bellet, Foukakis, Theodoros , Novik, Yelena , Rubovsky, Gabor , Metzger, Otto , Goulioti, Theodora , Law, Ernest H. , Carey, Lisa A. , Hlauschek, Dominik , Mayer, Erica L. , Gnant, Michael

Mayo Clinic

Cancer Research | March 8, 2022 | Volume: 82 | Issue: 4_Supplement | Pages: P4-12-01-P4-12-01

10.1158/1538-7445.sabcs21-p4-12-01 Get It

Abstract Background: As the development and use of oral anticancer agents increases, it is critical to understand patient adherence to both standard and investigational agents. The open label, phase 3 multicenter PALLAS trial investigates whether adding 2 years of the CDK4/6 inhibitor palbociclib (P) to adjuvant endocrine therapy (ET) improves invasive disease-free survival (iDFS) over adjuvant ET alone in patients (pts) with HR- positive, HR2-negative, stage II-III breast cancer. Pts were randomly assigned to either Palbociclib (125 mg/day, 3 weeks on, 1 week off, in a 28-day cycle) plus ongoing provider/patient-choice adjuvant ET (P+ET) versus ET alone. We examined patient-reported adherence to ET +/- P during the first two years of study treatment. Methods: Adherence outcomes were measured in English-speaking pts in the U.S., UK, Ireland and Australia, Spanish-speaking pts in Spain and Mexico, and German-speaking pts in Germany and Austria. Adherence measures included drug diaries completed at each cycle, pill counts (for P only) collected at each study visit, and the Morisky Medication Adherence Scale-4 item and the McHorney Adherence Estimator questionnaires completed at cycles 2, 3, 6, 12, 18, and 24 (22 months). Mean adherence for each cycle was defined as the average proportion of prescribed pills taken (via drug diary) across all patients who initiated that cycle. Persistence was defined as the duration of drug initiation to treatment cessation (via drug diary). Generalized estimating equations were used to model the “most adherent” pts on the Morisky (score = 5 vs score <5) and “low risk” for adherence problems on the McHorney (score=0 vs score >0) to compare the average difference between arms over time for ET, adjusting for baseline demographic and clinical variables. Results: 81% (N=4688) of PALLAS pts were included in this analysis. Median persistence to ET was 23.6 months in P + ET (n=2169), 23.7 months in ET alone (2136) and 20.4 months for P (n=2194). The number of pts who initiated each cycle for ET declined over time and was similar between arms; the decline was more marked for P (Table 1). Mean adherence range as measured by drug diary was 98.2-99.3% for ET in P+ET and 98.0 - 99.4% in ET alone; and for P, ranged from 93.4 - 98.8%. The adherence and persistence results were nearly identical whether measured by drug diary or pill count for P. The observed percent “most adherent” for P measured by the Morisky scale ranged from 71.9% - 79.6% and the percent “low risk” for adherence problems measured by the McHorney scale, 64.0% - 73.4%. The percent of pts “most adherent” and “low risk” for adherence problems to ET was higher, on average over time, in the P+ET group compared to ET alone (75% vs 68%, p<0.01; 75% vs 72%, p=.05, respectively). Conclusions: Self-reported mean adherence for both P + ET and ET alone was strikingly high for pts who remained on therapy; persistence was also high with ET during the 2-year treatment period. Current analyses suggest that nonadherence to either P or ET was likely not a major contributor to the iDFS results seen in the overall PALLAS trial. These results illustrate the importance of measuring and monitoring patient adherence to oral study agents. Support: AFT, Pfizer; ClinicalTrials.gov (NCT02513394) and EudraCT (2014-005181-30). https://acknowledgments.alliancefound.org Table 1.Adherence and persistence in PALLAS over the 24 month treatment periodPalbocicilb + ETETPalbociclibETETTreatment cycleMean Adherence (SD)N*Mean Adherence (SD)NMean Adherence (SD)N193.4 (13.8)229098.7 (6.1)230999.0 (5.2)2343294.7 (13.3)218198.8 (6.4)220398.4 (7.1)2206397.4 (10.1)211298.7 (7.3)214298.8 (6.3)2168497.6 (10.2)203598.6 (7.8)211099.0 (5.7)2154597.6 (11.1)197598.3 (7.9)209398.1 (8.3)2148698.1 (8.7)189998.7 (6.6)203798.5 (8.2)2116798.1 (9.3)185599.0 (6.3)201298.6 (7.3)2102898.0 (9.1)181098.2 (8.2)199798.1 (8.2)2092998.4 (7.4)173399.0 (6.4)196298.8 (6.8)20511098.3 (8.6)171499.2 (4.9)194699.0 (5.5)20381198.3 (8.0)169198.5 (7.3)193798.2 (8.2)20311298.7 (6.2)161299.1 (5.3)191098.7 (7.5)19861398.5 (7.7)159698.9 (6.4)189398.8 (7.1)19691497.9 (9.3)157698.4 (7.3)188298.0 (9.1)19611598.5 (6.9)151499.2 (4.6)185499.0 (6.0)19281698.2 (8.7)148699.1 (4.6)183599.1 (5.7)19131798.1 (9.8)147998.3 (7.8)182698.5 (6.4)19031898.7 (6.8)141699.3 (4.1)176899.2 (5.3)18601998.7 (7.3)140899.3 (3.8)175699.4 (3.1)18482098.4 (8.9)139798.9 (5.3)174298.7 (5.8)18382198.5 (7.5)130199.0 (6.1)167698.8 (7.1)17842297.8 (9.7)124698.8 (6.2)164799.2 (5.7)17692398.1 (8.8)118098.2 (8.5)161998.4 (8.0)17552498.8 (7.2)108699.0 (6.3)146898.9 (7.1)16192598.8 (6.7)99699.2 (5.2)143298.8 (7.1)15892697.9 (11.2)84599.1 (5.7)140998.6 (8.8)1578ET=Endocrine therapy * Number of pts who initiated the treatment cycle. Citation Format: Eileen Shinn, David Zahrieh, Angela DeMichele, Nick Zdenkowski, Julie Lemieux, Jun Mao, Vesna Bjelic-Radisic, Michelle Naughton, Georg Pfeiler, Karen Gelmon, Ingrid Mayer, Daniel Egle, Gabriele Zoppoli, Tiffany Traina, Miguel Martin Jiménez, Silvia Antolin Novoa, Tufia Haddad, Arlene Chan, Alistair Edward Ring, Antonio Wolff, Jose JuanPonce Lorenzo, Dhanusha Sabanathan, Hal Burstein, Zbigniew Ireneusz Nowecki, Gunda Pristauz-Telsnigg, Adam Brufsky, Meritxell Bellet-Ezquerra, Theodoros Foukakis, Yelena Novik, Gabor Rubovszky, Karoline Muehlbacher, Otto Metzger, Theodora Goulioti, Ernest Law, Ann Partridge, Lisa Carey, Alex Zoroufy, Dominik Hlauschek, Christian Fesl, Erica Mayer, Michael Gnant. Adherence with adjuvant endocrine therapy with or without Palbociclib in the PALLAS trial [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P4-12-01.
Associations Between Unprocessed Red Meat and Processed Meat With Risk of Recurrence and Mortality in Patients With Stage III Colon Cancer
Blarigan, Erin L. Van , Bainter, Tiffany M., Fuchs, Charles S. , Niedzwiecki, Donna , Hantel, Alexander, Benson, Al B. , Atienza, Daniel, Messino, Michael J., Kindler, Hedy L. , Sanoff, Hanna K. , Giovannucci, Edward L. , Ng, Kimmie , Meyerhardt, Jeffrey A. , Meyerhardt, Jeffrey A , Niedzwiecki, Donna , Sanoff, Hanna , Ou, Fang‐Shu , Zhang, Sui , Saltz, Leonard B. , Mayer, Robert J. , Venook, Alan P. , Ogino, Shuji

Mayo Clinic

JAMA Network Open | February 22, 2022 | Volume: 5 | Issue: 2 | Pages: e220145

10.1001/jamanetworkopen.2022.0145 | PMID 35191970 Get It